Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study
Identifieur interne : 001069 ( Main/Exploration ); précédent : 001068; suivant : 001070Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study
Auteurs : Vesna Sossi [Canada] ; Raúl De La Fuente-Fernández [Espagne] ; Michael Schulzer [Canada] ; Andre R. Troiano [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada]Source :
- Annals of Neurology [ 0364-5134 ] ; 2007-11.
Abstract
Objective: To investigate the role of the dopamine transporter (DAT) in the regulation of synaptic dopamine (DA) levels in Parkinson's disease and its role in the preservation of DA in presynaptic terminals. Methods: Ten Parkinson's disease patients (age, 62.9 ± 9.5 years; Unified Parkinson's Disease Rating Scale motor score in “off” state, 28.5 ± 8.2) underwent positron emission tomography with 11C‐methylphenidate (MP, a DAT marker), 11C‐dihydrotetrabenazine (a vesicular monoamine transporter 2 marker), and 18F‐fluorodopa, leading to the determination of the MP and 11C‐dihydrotetrabenazine binding potentials (BPs) and the effective distribution volume for 18F‐fluorodopa, the inverse of DA turnover. Seven patients also underwent positron emission tomography with 11C‐raclopride before and 1 hour after levodopa administration to estimate levodopa‐induced changes in synaptic DA concentration. Results: We found a significant positive correlation between effective distribution volume and BPMP (r = 0.93; p < 0.001) and a significant negative correlation between changes in synaptic DA concentration and BPMP (r = −0.93; p = 0.04), independent of disease severity and duration. Interpretation: These data show that in Parkinson's disease, greater DAT levels are directly associated with lower DA turnover and lower changes in synaptic DA concentration. This implies that an important functional role of DAT is to maintain relatively constant synaptic DA levels and to preserve DA in nerve terminals. A decrease in DAT, although potentially serving as a compensatory mechanism in early disease, may ultimately result in increased DA turnover and higher oscillations in synaptic DA concentration, thereby possibly predisposing toward the occurrence of motor complications as disease progresses. Ann Neurol 2007
Url:
DOI: 10.1002/ana.21204
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study</title><author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name></author><author><name sortKey="De La Fuente Ernandez, Raul" sort="De La Fuente Ernandez, Raul" uniqKey="De La Fuente Ernandez R" first="Raúl" last="De La Fuente-Fernández">Raúl De La Fuente-Fernández</name></author><author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name></author><author><name sortKey="Troiano, Andre R" sort="Troiano, Andre R" uniqKey="Troiano A" first="Andre R." last="Troiano">Andre R. Troiano</name></author><author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:08BB13C48E9346A6CED1EB2861551C3C7F51156E</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/ana.21204</idno><idno type="url">https://api.istex.fr/document/08BB13C48E9346A6CED1EB2861551C3C7F51156E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000D67</idno><idno type="wicri:Area/Main/Curation">000C07</idno><idno type="wicri:Area/Main/Exploration">001069</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study</title><author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="De La Fuente Ernandez, Raul" sort="De La Fuente Ernandez, Raul" uniqKey="De La Fuente Ernandez R" first="Raúl" last="De La Fuente-Fernández">Raúl De La Fuente-Fernández</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Division of Neurology, Hospital Arquitecto Marcide, Ferrol (A Coruña)</wicri:regionArea><wicri:noRegion>Ferrol (A Coruña)</wicri:noRegion></affiliation></author><author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Troiano, Andre R" sort="Troiano, Andre R" uniqKey="Troiano A" first="Andre R." last="Troiano">Andre R. Troiano</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>TRIUMF, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-11">2007-11</date><biblScope unit="volume">62</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="468">468</biblScope><biblScope unit="page" to="474">474</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">08BB13C48E9346A6CED1EB2861551C3C7F51156E</idno><idno type="DOI">10.1002/ana.21204</idno><idno type="ArticleID">ANA21204</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To investigate the role of the dopamine transporter (DAT) in the regulation of synaptic dopamine (DA) levels in Parkinson's disease and its role in the preservation of DA in presynaptic terminals. Methods: Ten Parkinson's disease patients (age, 62.9 ± 9.5 years; Unified Parkinson's Disease Rating Scale motor score in “off” state, 28.5 ± 8.2) underwent positron emission tomography with 11C‐methylphenidate (MP, a DAT marker), 11C‐dihydrotetrabenazine (a vesicular monoamine transporter 2 marker), and 18F‐fluorodopa, leading to the determination of the MP and 11C‐dihydrotetrabenazine binding potentials (BPs) and the effective distribution volume for 18F‐fluorodopa, the inverse of DA turnover. Seven patients also underwent positron emission tomography with 11C‐raclopride before and 1 hour after levodopa administration to estimate levodopa‐induced changes in synaptic DA concentration. Results: We found a significant positive correlation between effective distribution volume and BPMP (r = 0.93; p < 0.001) and a significant negative correlation between changes in synaptic DA concentration and BPMP (r = −0.93; p = 0.04), independent of disease severity and duration. Interpretation: These data show that in Parkinson's disease, greater DAT levels are directly associated with lower DA turnover and lower changes in synaptic DA concentration. This implies that an important functional role of DAT is to maintain relatively constant synaptic DA levels and to preserve DA in nerve terminals. A decrease in DAT, although potentially serving as a compensatory mechanism in early disease, may ultimately result in increased DA turnover and higher oscillations in synaptic DA concentration, thereby possibly predisposing toward the occurrence of motor complications as disease progresses. Ann Neurol 2007</div></front></TEI><affiliations><list><country><li>Canada</li><li>Espagne</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name></noRegion><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><name sortKey="Troiano, Andre R" sort="Troiano, Andre R" uniqKey="Troiano A" first="Andre R." last="Troiano">Andre R. Troiano</name></country><country name="Espagne"><noRegion><name sortKey="De La Fuente Ernandez, Raul" sort="De La Fuente Ernandez, Raul" uniqKey="De La Fuente Ernandez R" first="Raúl" last="De La Fuente-Fernández">Raúl De La Fuente-Fernández</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001069 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001069 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:08BB13C48E9346A6CED1EB2861551C3C7F51156E
|texte= Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study
}}
| This area was generated with Dilib version V0.6.23. |  |